Clinical trials: Pancreas Tumor
Pancreatic Cancer
Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006467
- Testing
- ISIS 2503, gemcitabine hydrochloride
- Where
- 16 sites in United States
- Volunteers
- 48 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Pancreatic Adenocarcinoma
S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer
This partially randomized phase I/II trial studies the side effects and best dose of pegylated recombinant human hyaluronidase (PEGPH20) when given together with combination chemotherapy and to see how well they work compared…
- Trial name
- NCT01959139
- Testing
- PEGPH20, Oxaliplatin, Leucovorin
- Where
- 154 sites in United States
- Volunteers
- 126 people
- Sponsor
- SWOG Cancer Research Network
Pancreatic Cancer
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine and nab-paclitaxel in previously untreated…
- Trial name
- NCT02047500
- Testing
- TH-302, Nab-paclitaxel, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- ImmunoGenesis
Pancreas Neoplasms
Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer
The purpose of this study is to test a combination-therapy of oxaliplatin and docetaxel in patients with metastatic or locally advanced adenocarcinoma of the pancreas after failure of a palliative first line therapy.
- Trial name
- NCT00690300
- Testing
- Docetaxel, Oxaliplatin
- Where
- 5 sites in Germany
- Volunteers
- 44 people
- Sponsor
- University of Ulm
Pancreatic Ductal Adenocarcinoma, Stage IA Pancreatic Cancer
Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy
This pilot research trial studies patient derived cancer cell lines in identifying molecular changes in patients with previously untreated pancreatic cancer and are receiving gemcitabine hydrochloride-based chemotherapy.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer
- Trial name
- NCT02414100
- Testing
- Laboratory Biomarker Analysis, Cytology Specimen Collection Procedure
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas
Study of SBP-101 in Pancreatic Cancer
This phase 1 first-in-human study evaluates safety and tolerability of SBP-101 in subjects with previously treated pancreatic ductal adenocarcinoma and will identify the maximum tolerated dose (MTD).
- Trial name
- NCT02657330
- Testing
- SBP-101
- Where
- 4 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- Panbela Therapeutics, Inc.
Pancreatic Ductal Adenocarcinoma, Chronic Pancreatitis
CT Pancreas Perfusion
1. Pancreatic CT perfusion with a biofeedback breathing belt worn by the participant, and using novel post-processing techniques, is a reliable method which can be used to differentiate between pancreatic cancer, chronic…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Chronic Pancreatitis, Autoimmune Pancreatitis
- Trial name
- NCT00588367
- Testing
- Mayo Interactive Breath Hold Monitor
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Pancreas Cancer, Localized Pancreas Cancer
Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer
A prospective evaluation of neoadjuvant FOLFIRINOX regimen in patients with non-metastatic pancreas cancer (Baylor University Medical Center and Texas Oncology Experience)
- Conditions
- Pancreas Cancer, Localized Pancreas Cancer, Non-metastatic Pancreas Cancer
- Trial name
- NCT01771146
- Testing
- FOLFIRINOX Regimen
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Baylor Research Institute
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
This phase I trial tests the safety, side effects, and best dose of calaspargase pegol-mknl in combination with cobimetinib in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8
- Trial name
- NCT05034627
- Testing
- Biopsy, Calaspargase Pegol-mknl, Cobimetinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- OHSU Knight Cancer Institute
Exocrine Pancreatic Cancer
PATAKESS Protocol : Clinical and Biological Analysis of Exocrine Pancreatic Tumors
PATAKESS is a monocentric non interventional cohort study (prospective (alive patients) and retrospective (dead patients with biological material from surgery and/or biopsies already collected)).
- Trial name
- PATAKESS (NCT04011982)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Centre Leon Berard
Non-Small Cell Lung Cancer, Prostate Cancer
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
The purpose of this study is to determine if TH-302, in combination with A) Gemcitabine, or B) Docetaxel or C) Pemetrexed methotrexate, are safe and effective in the treatment of Pancreatic Cancer, Castrate-resistant Prostate…
- Conditions
- Non-Small Cell Lung Cancer, Prostate Cancer, Pancreatic Cancer
- Trial name
- NCT00743379
- Testing
- TH-302
- Where
- 11 sites in United States
- Volunteers
- 71 people
- Sponsor
- Threshold Pharmaceuticals
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer
This clinical trial tests the safety, side effects, best dose and feasibility of using 64Cu-DOTA A2 scFv-Fc2 DM with positron emission tomography for the imaging of patients with PSCA-expressing pancreatic cancer that has spread…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- NCT07608627
- Testing
- Biospecimen Collection, Copper Cu 64-DOTA-A2DM, Positron Emission Tomography
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Neuroendocrine Tumors, Carcinoid Tumors
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
The goal of this clinical research study is to learn if the study drug, Pasireotide LAR can shrink or slow the growth of Metastatic Neuroendocrine Carcinomas. The safety of this drug will also be studied.
- Trial name
- NCT01253161
- Testing
- Pasireotide Long Acting Release (LAR)
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pancreas Cancer, Pancreatitis
Pancreas Registry and High Risk Registry
The purpose of this study is to establish a registry of patients with pancreatic diseases. Patients included in the registry may include those with: pancreatic cancer, precancerous lesions of the pancreas, inflammatory lesions of…
- Conditions
- Pancreas Cancer, Pancreatitis, Chronic Pancreatitis, Pancreatic Cyst
- Trial name
- NCT02775461
- Where
- 2 sites in United States
- Volunteers
- 1,368 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Pancreatic Cancer Stage I, Pancreatic Cancer Stage II
Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer
This is a case-control study to clinically validate the performance of a protein biomarker test to differentiate Stage I and Stage II pancreatic ductal adenocarcinoma (PDAC) patient samples from samples acquired from control…
- Conditions
- Pancreatic Cancer Stage I, Pancreatic Cancer Stage II, Cancer Diagnosis, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- CLARITI (NCT06947382)
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 1,066 people, healthy volunteers welcome
- Sponsor
- Immunovia, Inc.
Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC)
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
- Conditions
- Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- FIT-001 (NCT06026410)
- Testing
- Darlifarnib, Cabozantinib, Adagrasib
- Where
- 38 sites in United States, France and 3 more
- Volunteers
- 300 people
- Sponsor
- Kura Oncology, Inc.
Pancreatic Cancer, Lung Cancer
Perceptions of Exceptional Patients in Cancer Care Relating to Their Unusual Survival
The main objective of this study is to explore experiences and insights from exceptional patients, patients with cancer that were considered by their physicians as having exceptional course of survival related to their specific…
- Conditions
- Pancreatic Cancer, Lung Cancer, Stomach Cancer, Esophageal Cancer
- Trial name
- NCT02055313
- Volunteers
- 20 people
- Sponsor
- Meir Medical Center
Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with resectable and unresectable pancreatic cancer.
- Conditions
- Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma, Neoadjuvant Pancreatic Cancer
- Trial name
- NCT03138720
- Testing
- Paclitaxel Protein Bound (Abraxane)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- HonorHealth Research Institute
Pancreatic Cancer, Metastatic Breast Cancer
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Among patients with advanced (metastatic) cancers, detailed characterizations of the tumor utilizing genomic and proteonomic techniques may help guide treatment.
- Conditions
- Pancreatic Cancer, Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Colon Cancer
- Trial name
- NCT03073473
- Testing
- NantHealth GPS Cancer Test
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- Cota Inc.
Pancreas Cancer
Preoperative/Neoadjuvant Therapy and Vascular Debranching Followed by Resection for Locally Advanced Pancreatic Cancer
Pancreatic cancer continues to have a poor prognosis. Many patients are diagnosed with advanced disease. In a considerable proportion of these patients, the tumor has contact with or invades into arterial blood vessels supplying…
- Trial name
- PREVADER (NCT04136769)
- Testing
- Visceral Debranching
- Where
- 3 sites in Germany
- Volunteers
- 3 people
- Sponsor
- Ulrich Ronellenfitsch, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.